Demographics and clinical characteristics of patients with GI-ADRs associated with etanercept for inflammatory rheumatic diseases in the Dutch Biologic Monitor and DREAM registries.
| Patients With GI-ADRs in Dutch Biologic Monitor | Patients With GI-ADRs in DREAM Registries | |
|---|---|---|
| Patients, n | 25 | 9 |
| Age, yrs, mean ± SD | 57 ± 13 | 59 ± 8 |
| Female sex | 22 (88) | 7 (78) |
| Indication | ||
| Rheumatoid arthritis | 19 (76) | 9 (100) |
| Axial spondyloarthritis | 3 (12) | 0 |
| Psoriatic arthritis | 6 (24) | 0 |
| Combination therapy | 18 (72) | 5 (56) |
| Methotrexate | 12 (48) | 2 (22) |
| Corticosteroidsa | 1 (4) | 2 (22) |
| Sulfasalazine | 2 (8) | 2 (22) |
| Hydroxychloroquine | 3 (12) | 0 |
| Leflunomide | 1 (4) | 0 |
Values are expressed as n (%) unless otherwise indicated.
↵a Dutch Biologic Monitor: prednisolone (1); DREAM registries: prednisolone (1), triamcinolonacetonide used once (1). GI-ADR: gastrointestinal adverse drug reaction; DREAM: Dutch Rheumatoid Arthritis Monitoring.